Apollon Dareios Zare Chormizi

Mr. Apollon Dareios Zare Chormizi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
Chrysa VoyiatzakiChrysa Voyiatzaki
Chrysa Voyiatzaki
ACApollon Dareios Zare Chormizi
Apollon Dareios Zare Chormizi
MTMaria Tsoumani
Maria Tsoumani
ANTONIA EFSTATHIOUANTONIA EFSTATHIOU
ANTONIA EFSTATHIOU
KKKonstantinos Konstantinidis
Konstantinos Konstantinidis
MKMarika Kotsianopoulou
Marika Kotsianopoulou
This study aims to screen for IgG antibodies against Toxoplasma gondii (T. gondii) in the sera of 155 newly diagnosed Human Immunodeficiency Virus (HIV) positive patients under surveillance in Greek Infectious Disease Units. Additionally, risk factors based on patient demographics were examined, and a comparative evaluation of commercially available serological methods was conducted. Three methods were employed to detect IgG antibodies against T. gondii: Enzyme-Linked Immunosorbent Assay (ELISA), Indirect Immunofluorescence Antibody Test (IFAT), and Western Blot (WB), which was used as a reference here. Forty-nine sera samples were true-positive for IgG antibodies against T. gondii, resulting in a 31.61% positivity rate, and the immunoassay test statistical reliability analysis resulted in higher IFAT accuracy (90.97%) compared to ELISA (76.26%). Furthermore, statistical analysis of demographic and immunological data included in the study placed female and foreign/non-Greek individuals at 2.24 (p = 0.0009) and 2.34 (p = 0.0006) times higher risk of positive T. gondii IgG testing compared to their male and Greek counterparts, respectively. Our findings on positivity rates and comparative serology underscore the importance of early and suitable screening measures for newly diagnosed HIV+ patients to mitigate the life-threatening outcomes that may arise from a potential subsequent T. gondii activation.

10 July 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
Chrysa VoyiatzakiChrysa Voyiatzaki
Chrysa Voyiatzaki
ACApollon Dareios Zare Chormizi
Apollon Dareios Zare Chormizi
MTMaria Tsoumani
Maria Tsoumani
ANTONIA EFSTATHIOUANTONIA EFSTATHIOU
ANTONIA EFSTATHIOU
KKKonstantinos Konstantinidis
Konstantinos Konstantinidis
MKMarika Kotsianopoulou
Marika Kotsianopoulou
A serological screening was conducted to detect IgG antibodies against Leishmania infantum (L. infantum) in newly diagnosed human immunodeficiency virus (HIV) patients in Greece. The study also examined potential risk factors and the agreement of commercially available serological methods. IgG antibodies against L. infantum were detected using enzyme-linked immunosorbent assay (ELISA), indirect immunofluorescence antibody test (IFAT), and Western blot (WB). Out of 155 samples, 14 (9.0%) tested positive for IgG antibodies against L. infantum using at least two methods. Statistical analysis showed substantial agreement between WB and IFAT methods (Cohen’s kappa = 0.75) but moderate overall agreement among the three methods (Fleiss’ kappa = 0.42). Additionally, HIV+ intravenous drug users faced 3.55 times (p = 0.025) higher risk of testing positive for L. infantum IgG, positing that anthroponotic transmission between these patients is a plausible hypothesis based on existing literature. Non-invasive and cost-effective techniques are preferred to detect asymptomatic infections, and leishmaniasis screening should be conducted immediately after HIV diagnosis in endemic regions to enable prophylactic treatment for leishmaniasis in addition to antiretroviral therapy. To maximize sensitivity, performing at least two different serological methods for each patient is recommended.